FDA Approves The Atazanavir And Cobicistat Combination

Published Date: Jun 2015

The much awaited decision of the ‘FDA’ in January this years had backed great appreciation across the globe. The Food and Drug Administration of US finally approved the Evotaz or atazanavir combination that is now being used in blend with various ARV’s effective in treating HIV-1. Industry experts eyeing the global and Chinese atazanavir industry say the approval comes as a great boost for manufacturers such as Bristol- Myers Squibb and Gilead Sciences that manufacturers Reyataz and Tybost. Experts believe that the drug would increase the drug levels of various ARV’s.

Gaging at such amendments in the atazanavir business, Prof Research Reports has added a report titled “Global and Chinese Atazanavir Industry." The report highlights the market share and size, opportunities, trends, value chain analysis, consumption volume and opportunities among various other factors spurring growth in atazanavir segment in China. The head of global market at Bristol- Myers Squibb, Murdo Gordon in a press release said “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations,"

The FDA has seconded the use of atazanavir and cobicistat to treat adults combating HIV infection.  Medical professionals advocate Atazanavir/cobicistat as a fixed –dose blend tablets which comprises of around 300 mg and 150 mg atazanavir and cobicistat respectively. Murdo on FDA approval explained "We are pleased to provide physicians and patients with an important new option to treat HIV; atazanavir with cobicistat delivers sustained efficacy and safety through 48 weeks, as demonstrated through its rigorous clinical development plan, including a head-to-head Phase III trial."

Share This News
facebooktwitterlinkedingoogleplusstumbleuponreddit
24/7 Customer Support
check Have questions?
Direct
+1-971-202-1575
Toll Free
+1(855)711-1555 or2
email help@profresearchreports.com
Market Research

Prof Research Report is a high end market research & consulting firm that offers current and future market intelligence across 30 industrial verticals such as energy, new materials, transportation, daily consumer goods, chemicals, etc through is quality database. Prof Research Report has successfully utilized technology to manage complex and massive market related database, which offers research reports of high analytical value. Prof Research Report’s aim is to help our clients in achieving sustainable growth by providing insightful and qualitative research reports. Our research reports help our clients to achieve the competitive edge in the market.

Vision:

To be a world class provider of market research reports.

Mission:

To create a database of reliable and accurately analyzed report and be the decision making support for our clients.

CONTACT 5320 SW MACADAM AVENUE, SUITE 100, PORTLAND, OR 97239, UNITED STATES. © 2016. ALL RIGHTS RESERVED PROF RESEARCH REPORTS.